Description
Manufacturer
BAXTER ONCOLOGY GMBH(GERMANY)
Registraction Number
MAL20101997ACRZ
Here’s a summary of VIDAZA Powder for Suspension for Injection 100 mg/vial:
Contents
Active Ingredient: Azacitidine (100 mg per vial).
Inactive Ingredients: Mannitol (100 mg per vial).
Indications
Used for the treatment of myelodysplastic syndromes (MDS), including:
Refractory anemia.
Chronic myelomonocytic leukemia (CMML).
Acute myeloid leukemia (AML) with multilineage dysplasia.
Helps restore normal blood cell production and reduce the need for blood transfusions.
Instructions
Dosage: Administered subcutaneously or intravenously as prescribed by a healthcare professional.
Typical dose: 75 mg/m² daily for 7 days, repeated every 28 days.
Preparation:
Reconstitute the powder with sterile water for injection to create a suspension.
Use immediately after preparation or store under recommended conditions.
Precautions:
Regular monitoring of blood counts and liver function is required.
Not suitable for individuals with advanced malignant hepatic tumors or hypersensitivity to Azacitidine.
Storage: Keep below 25°C, protected from light.
More detail about Complete Wellness
Malaysia
